Aug 14, 2023 / 04:00AM GMT
Operator
Good morning, ladies and gentlemen. Welcome to the Q1 FY '24 Earnings Conference Call of Glenmark Pharmaceuticals Limited.
(Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Utkarsh Gandhi, General Manager, Investor Relations, for Glenmark Pharmaceuticals. Thank you.
And over to you, sir.
Utkarsh Gandhi -
Thank you, Lizan. Good morning, everyone, and welcome to the Q1 FY '24 Results Conference Call of Glenmark Pharmaceuticals Limited. Let us review the overall performance of the company for the first quarter of FY '24.
Glenmark's consolidated revenue from operations for the first quarter of FY '24 was at INR 34,106 million (sic) [INR 34,016 million], as against INR 27,773 million in the corresponding quarter last year, recording an overall year-on-year growth of 22.5%. We'll review each of the businesses of Glenmark Pharmaceuticals Limited, starting off with India.
Sales from the formulation business in India for Q1 FY '24 were at INR 10,643 million, as
Q1 2024 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Mar 20, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers